Evidence map›Paper›PMID 37945594›Full record

ArticleScientific reports2023

The integrative multi-omics approach identifies the novel competing endogenous RNA (ceRNA) network in colorectal cancer.

Ghanbar Mahmoodi Chalbatani, Elahe Gharagouzloo, Mohammad Amin Malekraeisi, Paniz Azizi, Amirabbas Ebrahimi, Michael R Hamblin, Habibollah Mahmoodzadeh, Eyad Elkord, Seyed Rohollah Miri, Mohammad Hossein Sanati and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 3 countries.

Ghanbar Mahmoodi Chalbatani *Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Science, Tehran, Iran.
Elahe Gharagouzloo *Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Science, Tehran, Iran.
Mohammad Amin MalekraeisiStudent Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Paniz AziziPsychological and Brain Science Departments, Program in Neuroscience, Indiana University, Bloomington, IN, USA.
Amirabbas EbrahimiCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Science, Tehran, Iran.
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, 40 Blossom Street, Boston, MA, 02114, USA.
Habibollah MahmoodzadehCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Science, Tehran, Iran.
Eyad ElkordDepartment of Applied Biology, College of Science, University of Sharjah, Sharjah, United Arab Emirates. e.elkord@salford.ac.uk.
Seyed Rohollah MiriCancer Research Center, Cancer Institute of Iran, Tehran University of Medical Science, Tehran, Iran. drsrmiri@yahoo.com.
Mohammad Hossein SanatiDivision of Cellular and Molecular Biology, Department of Biology, Nour Danesh Institute of Higher Education, Meymeh, Isfahan, Iran. m_sanati@nigeb.ac.ir.
Bahman PanahiDepartment of Genomics, Branch for Northwest and West Region, Agricultural Biotechnology Research Institute of Iran (ABRII), Agricultural Research, Education and Extension Organization (AREEO), Tabriz, Iran.
Motamed Cancer Institute · IRNourDanesh Institute of Higher EducationAgricultural Research & Education Organization · IRIndiana University Bloomington · USIran University of Medical Sciences · IRMassachusetts General Hospital · USUniversity of Sharjah · AEUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNAs (circRNA) are known to function as competing endogenous RNA (ceRNA) in various cancers by regulating microRNAs (miRNA). However, in colorectal cancer (CRC), the precise pathological role of circ000240/miRNA/mRNA remains indeterminate. The expression level of hsa_circ_000240 was evaluated using qRT-PCR in matching pairs of CRC tumor and adjacent normal tissue samples in our laboratory. Then, to determine whether hsa_circ_000240 acted as a ceRNA in CRC, the linked miRNAs and gene targets were retrieved. Topological analysis of candidate genes using a network approach identified the most critical hub genes and subnetworks related to CRC disease. Microarray and bulk RNA sequencing analyses were utilized to comprehensively evaluate the expression levels of both miRNA and mRNA in CRC. Single-cell RNA-seq analysis was also used to evaluate the significant overall survival (OS) genes at the cellular level. ATAC-seq data provided insights into candidate genes' accessible chromatin regions. The research uncovered a considerable upregulation of hsa_circ_000240 in CRC tissues. Three miRNAs interacted with the target circRNA. One thousand six hundred eighty intersected genes regulated by three miRNAs were further identified, and the relevant functionality of identified neighbor genes highlighted their relevance to cancer. The topological analysis of the constructed network has identified 33 hub genes with notably high expression in CRC. Among these genes, eight, including CHEK1, CDC6, FANCI, GINS2, MAD2L1, ORC1, RACGAP1, and SMC4, have demonstrated a significant impact on overall survival. The utilization of single-cell RNA sequencing unequivocally corroborated the augmented expression levels of CDC6 and ORC1 in individuals with CRC, alongside their noteworthy connection with the infiltration of immune cells. ATAC-seq analyses revealed altered accessibility regions in Chr2, 4, and 12 for CDC6 and ORC1 high-expression. Correlation analysis of CDC6 and ORC1 further highlighted the association of candidate gene expression with exhaustion markers such as CTLA4, CD247, TIGIT, and CD244. The candidate genes exhibit a positive correlation with chromatin remodeling and histone acetylation. These epigenetic modifications play a significant role in influencing the cancer progression following expression of CDC6 and ORC1 in CRC. Additionally, results showed that the methylation rate of the promoter region of CDC6 was elevated in CRC disease, confirming the functional importance of CDC6 and their interaction with hsa_circ_000240 and associated ceRNA in CRC. In conclusion, this study highlights hsa_circ_000240's role as a ceRNA in CRC. It opens new avenues for further dissection of CDC6, ORC1, and underlying novel epigenetics and immunotherapy targets for CRC therapy.

Indexed as

Colorectal NeoplasmsMicroRNAsChromosomal Proteins, Non-HistoneHumansMultiomicsRNA, CircularRNA, MessengerChromosomal Proteins, Non-HistoneGINS2 protein, humanMicroRNAsRNA, CircularRNA, Messenger

Identifiers

PMID37945594
PMCPMC10636147
OpenAlexW4388529699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.